Home /Insights Insights NewsANVISA Accreditation renewed successfully for Lambda’s Ahmedabad and Mehsana FacilitiesBlogEarly PhaseClinical Insights from a Bioequivalence Study of Pertuzumab 420 mg Solution for InfusionBlogLabsBioanalytical Assays – Methods LibraryBlogPharmacovigilanceServices & CapabilitiesQualified Person for Pharmacovigilance (QPPV): Strengthening Compliance Across the EU and UKServices & CapabilitiesEnrollment Excellence in Phase-3 Semaglutide Trials – 514 Patients in Just 2 MonthsServices & CapabilitiesBioanalytical Methods / Assay List (Lambda & Novum)BlogStudy Insights: Phase-I, Bioequivalence Study of Trastuzumab SC InjectionBlogSpecialized Clinical Development Support for Semaglutide ProgramsNewsBioanalytical Excellence Upheld – Unannounced US FDA inspection concludes with Zero 483sNewsLambda Successfully Completes US FDA Pharmacovigilance Inspection with Zero 483s – 4th Consecutive in One YearClinical Research UpdateClinical Research Update – June 2025BlogClinical ResearchFull-Service CRO | End-to-End Expertise for Every Phase of Clinical DevelopmentClinical Research UpdateClinical Research Update – May 2025Case-StudyInsights: Bioequivalence Study of Semaglutide InjectionBlogLabsStudy Insights: Bioequivalence Study of Semaglutide Injection 1.34 mg/ml (2 mg/1.5 mL)BlogLate PhaseOvarian Cancer Clinical Trials – Advancing Research Through Patient-Focused ApproachesNewsLambda Ahmedabad Successfully Completes USFDA Inspection without any 483 ObservationsBiosimilarServices & CapabilitiesEnd-to-end Biosimilar Development and Clinical Trials ExpertiseLate PhaseServices & CapabilitiesAdvancing Late Phase Clinical TrialsClinical Research UpdateClinical Research Update – April 2025BlogLate PhaseStrategic Endpoint Selection for Successful Oncology Clinical TrialsBlogClinical ResearchNavigating CDSCO Regulations: Key Approval Processes and Lambda’s Regulatory SupportNewsUSFDA Approves ANDA for Protein-Bound Paclitaxel Injection: Program supported by Lambda as the key Bioanalytical PartnerBlogLate PhaseAdvancing Clinical Development in Women’s HealthBlogLabsA Highly Precise, Accurate, and Robust LC-MS/MS Method for the Quantification of Semaglutide in Human PlasmaNewsLambda Successfully Completes Multi-Site EMA Inspection for Biosimilar ProductClinical Research UpdateClinical Research Update – March 2025NewsLambda Successfully Completes Swissmedic Inspection for Pharmacovigilance ServicesClinical Research UpdateClinical Research Update – February 2025NewsSuccessful completion of the Ministry of Health inspection of the Republic of Kazakhstan (October 2024)BlogLate PhasePatient-Centric Trials in Advancing Cancer Research: A Journey of Progress & HopeBlogPharmacovigilanceEnsuring Drug Safety: Lambda’s Pharmacovigilance Milestones in 2024Clinical Research UpdateClinical Research Update – January 2025NewsLambda Excels in US FDA Inspection for PV with Zero Findings – 3rd Success in 2024BlogEarly PhaseNutraceuticals and Consumer Products Studies: Ensure product safety & efficacy with expert-led trialsBlogLate PhaseAdvancing Prostate Cancer Clinical Trials: Key InsightsClinical Research UpdateClinical Research Update – Lambda Newsletter – December 2024BlogLabsSummation of Similar Product Ions for Improved LC-MS-MS Quantitation: Advancing Peptide AnalysisBlogClinical ResearchWhat are Clinical Trials? Unlocking the Basics and the Critical ImportanceClinical Research UpdateUnderstanding Clinical Trials: A Beginner’s Guide to Clinical Research
BlogEarly PhaseClinical Insights from a Bioequivalence Study of Pertuzumab 420 mg Solution for Infusion
BlogPharmacovigilanceServices & CapabilitiesQualified Person for Pharmacovigilance (QPPV): Strengthening Compliance Across the EU and UK
Services & CapabilitiesEnrollment Excellence in Phase-3 Semaglutide Trials – 514 Patients in Just 2 Months
NewsLambda Successfully Completes US FDA Pharmacovigilance Inspection with Zero 483s – 4th Consecutive in One Year
BlogClinical ResearchNavigating CDSCO Regulations: Key Approval Processes and Lambda’s Regulatory Support
NewsUSFDA Approves ANDA for Protein-Bound Paclitaxel Injection: Program supported by Lambda as the key Bioanalytical Partner
BlogLabsA Highly Precise, Accurate, and Robust LC-MS/MS Method for the Quantification of Semaglutide in Human Plasma
NewsSuccessful completion of the Ministry of Health inspection of the Republic of Kazakhstan (October 2024)
BlogEarly PhaseNutraceuticals and Consumer Products Studies: Ensure product safety & efficacy with expert-led trials
BlogLabsSummation of Similar Product Ions for Improved LC-MS-MS Quantitation: Advancing Peptide Analysis
